Nephros, Inc. was founded in 1997 by Columbia University health professionals, scientists and engineers to improve the quality of life for the End Stage Renal Disease (ESRD) patient, while addressing the critical needs of the care provider. The Company has developed the most effective ESRD therapy available worldwide, offering unique and proprietary technologies that dramatically improve clinical efficacy. Nephros technologies also remove a range of harmful substances not currently removed by existing dialysis methods; addressed specifically are substances known collectively as middle molecules, due to their molecular weight, that contribute to such conditions as carpal tunnel syndrome, dialysis related amyloidosis, and degenerative bone disease in the ESRD patient.

Founded in 1997 to address current voids in ESRD treatment:

• Stale Methodologies
• Cost and Reimbursement Issues
• Quality of Care Issues

Nephros technology focus:

• Unique and cost-effective proprietary technologies
• Marked improvements in treatment efficacy per unit time
• Platforms: easy to use and maintain
• Technology that integrates well with existing mfg and clinical infrastructures